[News Article]Bio Connection Australia 2019

1 Jul 2019
Bio Connection Australia 2019
News Article

PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo,

Chairman and Chief Executive Officer of PharmAbcine is invited as keynote speaker and panelist to give a presentation and panel discussion at Bio Connection Australia organized by INFORMA in Melbourne 

on August 19th-20th, 2019 

(https://www.informa.com.au/event/conference/bio-connections-australia/ utm_source=Web_PDF&utm_medium=PDF&utm_content=PDF&utm_campaign=P19A13 ) . 

Dr. Yoo will share the experience as follows:

1. Olinvacimab (previously Tanibirumab or TTAC-0001) Phase IIa with recurrent GBM trials completed on June 2017

(the last patient release) and completed with its CSR(Clinical Study Report) on March 2018.

2. Olinvacimab + Keytruda combo phase Ib with metastatic Triple Negative Breast Cancer ongoing trial.

3. Olinvacimab + Keytruda combo phase Ib with recurrent GBM ongoing trial. 

He also will share the preparation for next coming trials.

4. Olinvacimab phase II Avastin recurrent/relapsed recurrent GBM at Olivia Newton John Cancer Center in Melbourne joint trials with Stanford University Cancer Center and Florida Cancer Center in the States.

5.  Olinvacimab + Keytruda combo phase II with metastatic Triple Negative Breast Cancer global trial including Australia.

6.  Olinvacimab + Keytruda combo phase II with recurrent GBM global trial including Australia.  

Please check the attached file for details.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.